Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | TACR1 | P25103 | 1/20 | 0.48 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2769697 | 0.85 | PREP (0.60) | PREPNPSR1FKBP1AALDH1A1TSHR | |
| SCHEMBL1056362 | 0.85 | PREP (0.60) | PREPNPSR1FKBP1AALDH1A1TSHR | |
| SCHEMBL1694132 | 0.84 | PREP (0.52) | PREPNPSR1FKBP1AALDH1A1TSHR | |
| SCHEMBL2760307 | 0.84 | PREP (0.52) | PREPNPSR1FKBP1AALDH1A1TSHR | |
| SCHEMBL1694135 | 0.84 | PREP (0.52) | PREPNPSR1FKBP1AALDH1A1TSHR | |
| SCHEMBL15215546 | 0.84 | PREP (0.52) | PREPNPSR1FKBP1AALDH1A1TSHR | |
| SCHEMBL1694136 | 0.84 | PREP (0.52) | PREPNPSR1FKBP1AALDH1A1TSHR | |
| SCHEMBL13703421 | 0.82 | CARM1 (0.48) | NPSR1TACR1FKBP1AALDH1A1MEN1 | |
| SCHEMBL2760273 | 0.80 | FKBP1A (0.49) | PREPNPSR1FKBP1AALDH1A1TSHR | |
| SCHEMBL11293050 | 0.80 | POLB (0.48) | FKBP1ATSHRL3MBTL1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049110-B1 | BRIDGED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-08-20 | — | — | EP | disclosed |
| US-20090239843-A1 | Bridged diazepan orexin receptor antagonists | MERCK SHARP & DOHME LLC | 2009-09-24 | — | — | US | disclosed |
| WO-2008008517-A2 | BRIDGED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239843-A1 | Bridged diazepan orexin receptor antagonists | HCRTR2, HCRTR1, CRHR1 | PREP 484/4885NPSR1 7/4885TACR1 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.